Cibus (CBUS) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
13 Aug, 2026Executive summary
CEO transition completed, with a focus on scaling revenue through proprietary, IP-protected platforms and prioritizing programs closest to commercialization, including Rice and Sustainable Ingredients.
Advanced commercialization in Rice and Sustainable Ingredients, with expanded partnerships and regulatory alignment in the US, EU, and Latin America.
Commercial progress includes converting industry conversations into ongoing partnerships, with seed companies seeking continuous trait improvements across crops.
Leadership transition completed with new CEO and continued cost reduction initiatives, targeting $35M annual net cash usage exiting 2026.
Focused on commercial ramp-up of biofragrance products and partner-funded lauric oils program in soybean.
Financial highlights
Q2 2026 revenue was $1 million, up from $0.9 million year-over-year; six-month revenue rose 36% to $2.7 million, driven by Sustainable Ingredients.
Net loss for Q2 2026 was $22.1 million, improved from $26.6 million year-over-year; net loss per share was $0.29, down from $0.61.
R&D expenses dropped to $8.5 million from $12.2 million, and SG&A to $5.4 million from $6.6 million, reflecting cost-saving initiatives.
Cash and equivalents stood at $20.4 million as of June 30, 2026; cash usage declined 19% sequentially and 31% year-over-year.
Net cash used in operating activities for H1 2026 was $20.9 million, down from $25.4 million year-over-year.
Outlook and guidance
Existing cash is expected to fund operations into early Q1 2027; annual net cash usage run-rate targeted at ~$35 million exiting 2026.
Rice royalty revenue expected to begin in 2028, ramping through 2029 as adoption expands; peak annual royalty opportunity exceeds $200 million.
Sustainable Ingredients program in commercial ramp-up, with additional scale-up orders anticipated in H2 2026.
Expects continued operating losses for several years as commercial activities scale; additional capital required to support business plans.
Board evaluating strategic alternatives to support funding needs.
Latest events from Cibus
- Gene editing accelerates crop innovation and royalty growth as global regulatory support expands.CBUS
LD Micro Main Event XIX Investor Conference - EU regulatory shift accelerates gene editing commercialization and royalty growth prospects.CBUS
Sidoti Small-Cap Virtual Investor Conference - Directors re-elected, executive pay approved, and auditor ratified with no shareholder questions.CBUS
AGM 2026 - Biotech firm targets $200M in offerings amid liquidity concerns and potential shareholder dilution.CBUS
Registration filing - Revenue up, net loss down, and cash funds operations into late Q1 2027; more capital needed.CBUS
Q1 2026 - Annual meeting covers director elections, executive pay, auditor ratification, and governance policies.CBUS
Proxy filing - Key votes include director elections, executive pay approval, and auditor ratification for 2026.CBUS
Proxy filing - Q3 net loss of $201.5M from goodwill impairment; cost savings and commercialization ongoing.CBUS
Q3 2024 - Gene editing is transforming agriculture with rapid regulatory acceptance and high-margin royalty models.CBUS
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024